Home » Stocks » VBI Vaccines

VBI Vaccines, Inc. (VBIV)

Stock Price: $2.47 USD 0.01 (0.49%)
Updated Oct 27, 2020 12:18 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 571.52M
Revenue (ttm) 1.82M
Net Income (ttm) -44.91M
Shares Out 231.20M
EPS (ttm) -0.27
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 27, 2020
Last Price $2.47
Previous Close $2.46
Change ($) 0.01
Change (%) 0.49%
Day's Open 2.47
Day's Range 2.38 - 2.49
Day's Volume 1,095,309
52-Week Range 0.53 - 6.93

More Stats

Market Cap 571.52M
Enterprise Value 502.67M
Earnings Date (est) Nov 4, 2020
Ex-Dividend Date n/a
Shares Outstanding 231.20M
Float 209.54M
EPS (basic) -0.26
EPS (diluted) -0.27
FCF / Share -0.18
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 37.33M
Short Ratio 4.59
Short % of Float 17.81%
Beta 1.73
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 314.02
PB Ratio 4.77
Revenue 1.82M
Operating Income -43.87M
Net Income -44.91M
Free Cash Flow -38.90M
Net Cash 68.85M
Net Cash / Share 0.30
Gross Margin -312.25%
Operating Margin -2,410.22%
Profit Margin -2,467.50%
FCF Margin -2,137.53%
ROA -17.03%
ROE -44.27%
ROIC -366.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(173.06% upside)
Current: $2.47
Target: 6.75
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-33.8%287.86%57.85%-42.62%-
Gross Profit-5.68-1.15-4.33-3.12-2.80
Operating Income-52.40-60.41-37.28-24.85-23.76
Net Income-54.81-63.60-39.00-23.21-26.19
Shares Outstanding11965.6544.1630.0412.63
Earnings Per Share-0.46-0.97-0.88-0.77-2.07
Operating Cash Flow-48.71-45.53-31.38-18.52-9.09
Capital Expenditures-3.67-5.99-0.64-0.59-0.58
Free Cash Flow-52.39-51.53-32.02-19.10-9.68
Cash & Equivalents44.2159.2767.6932.2812.48
Total Debt16.3014.0313.1411.96-
Net Cash / Debt27.9145.2454.5620.3312.48
Book Value88.2698.13120-83.7312.19
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name VBI Vaccines, Inc.
Country United States
Employees 123
CEO Jeffrey R. Baxter

Stock Information

Ticker Symbol VBIV
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: VBIV


VBI Vaccines, a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology in Israel, the United States, and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for a functional cure of chronic hepatitis B. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the target virus to elicit a potent immune response. Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. In addition, the company engages in the development of vaccine platforms and products for licensing to pharmaceutical companies and biotechnology companies. It primarily serves physicians and pharmacists through direct sales. VBI Vaccines Inc. has collaboration and license agreements with Brii Biosciences Limited; and GlaxoSmithKline Biologicals S.A. It also has a collaboration with the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.